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AbstrAct
Background Mutations in genes encoding ion channels 
or sarcomeric proteins are an important cause of 
hereditary cardiac disease. However, the severity of the 
resultant disease varies considerably even among those 
with an identical mutation. Such clinical variation is often 
thought to be explained largely by differences in genetic 
background or ‘modifier genes’. We aimed to test the 
prediction that identical genetic backgrounds result in 
largely similar clinical expression of a cardiac disease 
causing mutation, by studying the clinical expression of 
mutations causing cardiac disease in monozygotic twins.
Methods We compared first available clinical information 
on 46 monozygotic twin pairs and 59 control pairs that 
had either a hereditary cardiomyopathy or channelopathy.
Results Despite limited power of this study, we found 
significant heritability for corrected QT interval (QTc) in 
long QT syndrome (LQTS). We could not detect significant 
heritability for structural traits, but found a significant 
environmental effect on thickness of the interventricular 
septum in hypertrophic cardiomyopathy.
Conclusions Our study confirms previously found robust 
heritability for electrical traits like QTc in LQTS, and adds 
information on low or lacking heritability for structural 
traits in heritable cardiomyopathies. This may steer the 
search for genetic modifiers in heritable cardiac disease.
IntRoduCtIon
A number of hereditary cardiac diseases are 
caused by autosomal dominantly inherited, 
single gene mutations.1 2 Still, the extent 
and severity of the main cardiac abnormality 
caused by such mutations varies considerably 
between mutation positive subjects. Causes 
for this variability are largely unknown. It is 
widely speculated that this variability may be 
caused by variation in genes other than the 
mutated one, for instance by altering the 
clinical expression of the disease- causing 
mutation.3 This assumption predicts that 
two carriers of such a mutation who have an 
identical genome should have quite similar 
clinical expression of the mutation they both 
carry. Based on this idea, it is expected that 
recently developed high- throughput technol-
ogies may identify additional genetic variants 
that modify the cardiomyopathy or channel-
opathy.4
However, it is unclear whether this expec-
tation is justified, as it has not yet been tested 
to what extent identical genomes indeed 
result in a comparable clinical expression of a 
disease- causing mutation. Here, we tested this 
by analysing whether mutation- positive mono-
zygotic twins are more concordant for the 
main disease trait than mutation- positive dizy-
gotic twins or siblings. We analysed clinical 
data from twins counselled in high- volume 
cardiogenetic centres around the world and 
added data from twins on whom data were 
available publicly.
Monozygotic twins illuminate the genomic 
contribution to complex diseases.5–7 Twin 
studies are based on the assumptions that 
Key messages
What is already known about this subject?
 ► Mutations in genes encoding ion channels or sarco-
meric proteins are an important cause of hereditary 
cardiac disease. However, the severity of the resul-
tant disease varies considerably even among those 
with an identical mutation. This may be caused by 
genetic or environmental factors.
What does this study add?
 ► This study confirms previously found robust herita-
bility for electrical traits like corrected QT interval 
in long QT syndrome and adds that heritability for 
structural traits in heritable cardiomyopathies is 
likely low.
How might this impact on clinical practice?
 ► The results of this study will probably not alter clin-
ical practice, but do provide information that may 
steer the search for genetic modifiers in heritable 
cardiac disease.
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Table 1 Monozygotic twin pairs and control pairs of which 
data were available for this study per disease
Monozygotic twin pairs Control pairs
N
Cases
N
(zygosity tested)
From 
literature
N
N
(dizygotic 
twin pairs)
DCM 10 6 (5) 4 15 (0)
HCM 11 6 (5) 5 14 (2)
LQTS 25 24 (17) 1 30 (9)
Total 46 36 (27) 10 59 (11)
DCM, dilated cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; LQTS, long QT syndrome.
(1) monozygotic twin pairs share 100% of their genome, 
and therefore share additive genetic effects (the added 
effect at a single locus of one allele added to the effect of 
the other allele) and dominance effects (effects of inter-
action between two alleles on the same locus); (2) dizy-
gotic twin pairs and normal siblings share 50% of their 
genome, so they share 50% of the variance in additive 
genetic effects and 25% of the variance in dominance 
effects8; (3) monozygotic and dizygotic twin pairs share 
common environmental effects to the same extent.9 10 
For this study, we assumed that non- twin siblings share 
common environmental effects to the same extent as twin 
siblings. Although it is well known that even monozygotic 
twins do not have identical genomes,11 the current anal-
ysis allows to estimate the probability to find modifiers 
based on high- throughput genomic sequencing.
MetHods
We collected monozygotic twin pairs with dilated cardio-
myopathy (DCM), hypertrophic cardiomyopathy (HCM) 
or long QT syndrome type 1, 2 or 3 (LQTS) from fami-
lies with a high suspicion of familial disease in which a 
(likely) pathogenic mutation was identified. In total, we 
recruited 36 monozygotic twin pairs from Amsterdam 
and Groningen (The Netherlands), Rochester New York 
and Rochester Minnesota (USA), Helsinki (Finland), 
Pavia and Firenze (Italy), Umea (Sweden), Copenhagen 
(Denmark), Paris (France) and Murcia (Spain). In all 
cases, monozygosity was established on clinical grounds, 
while in 27 pairs (75%), monozygosity was confirmed 
using polymorphic DNA markers. In addition, we added 
detailed clinical data on 10 pairs of monozygotic twins 
with a cardiomyopathy or LQTS, in which a pathogenic 
mutation was identified or inherited disease was strongly 
suspected, from previously published studies.7 12–21 Taken 
together, we collected data on 46 monozygotic twin pairs 
(table 1). As a control group, we collected data on 59 pairs 
of same- sex dizygotic twins or same- sex normal siblings 
(table 1). We included only same- sex control pairs to 
avoid sex- induced within- pair differences. These cases 
were selected from families in which one of the afore-
mentioned hereditary cardiac diseases was diagnosed. 
Only retrospectively collected data were used in an 
anonymised database, which is in line with the guidelines 
for retrospective data analysis of the Amsterdam UMC 
institutional review board.
We retrospectively collected first available data on left 
ventricular ejection fraction (LVEF) and left ventricular 
end- diastolic dimension (LVEDD) in DCM, diastolic 
interventricular septum thickness (IVSd) in HCM and 
corrected QT interval (QTc, calculated using Bazett’s 
formula) for LQTS QTc (online supplementary table S1). 
We obtained values taken from the first available examina-
tions, where the time between the measurements of two 
individuals within a pair did not exceed 10% of the age 
of the oldest individual. An exception to this were seven 
pairs (six of which were control pairs) where early data 
were available only for the more severely affected indi-
vidual, while the less affected individual was only studied 
at a later age. For 13 LQTS control pairs, individuals were 
tested for the first time at different ages in the context of 
family counselling (online supplementary table S2).
We found no differences in age or sex between the 
monozygotic twins and the control group using Mann- 
Whitney (two- tailed) U tests (table 2). As all pairs are sex- 
matched and the heritability estimations are performed 
using the relation between two members of a pair, and the 
tests were performed at the same age for both members 
of a pair, we did not correct for age or sex differences 
before performing the heritability estimations.
To calculate the genetic contribution to a trait, we used 
structural equations modelling (SEM). When assessing 
the heritability of traits, the phenotypic variance can be 
split into genetic and environmental components and 
further divided into four components: A (additive genetic 
effects, which is narrow- sense heritability h2), D (domi-
nance effects), C (common environmental effects) and 
E (environmental effects unique to the individual). ACE 
(additive genetic effects, common and unique environ-
mental effects), AE (additive genetic effects and unique 
environmental effects) and CE (common and unique 
environmental effects) models were fitted and assessed 
for goodness of fit using the Akaike Information Crite-
rion (AIC) where a low AIC indicates a good fit.8
Results
We compared first available clinical information on 
disease traits in 46 monozygotic twin pairs and in 59 
control pairs of same- sex dizygotic twins or same- sex 
normal siblings (table 1). We found no differences in age 
or sex between the monozygotic twins and the control 
group (table 2). The results of the narrow- sense trait 
heritability (h2) estimations are summarised in figure 1 
and table 3. SEM yielded an h2 of 4.9% (95% CI 0.0% to 
84.5%) for LVEF and 52.8% (95% CI 0.0% to 91.2%) for 
LVEDD in DCM, 0.0% for IVSd (95% CI 0.0% to 43.6%) 
in HCM and 57.5% for QTc values in LQTS (95% CI 
5.5% to 87.5%).
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Table 2 Baseline characteristics for the monozygotic twin pairs and control pairs per disease
Monozygotic twin pairs Control pairs
Significance
(Mann- Whitney U test,
2- tailed)
DCM LVEF N 8 11
Age, years
(median, IQR)
51.4 (24.0) 49.6 (25.6) 0.52
Male (pairs, %) 4 (50%) 3 (27%) 0.16
LVEF, %
(median, IQR)
32.0 (20.0) 52.3 (31.7) 0.001**
LVEDD N 7 15
Age, years
(median, IQR)
45.9 (21.1) 50.4 (29.4) 0.30
Male (pairs, %) 3 (43%) 6 (40%) 0.86
LVEDD, mm
(median, IQR)
55.5 (6.3) 54.7 (7.8) 0.41
HCM IVSd N 11 14
Age, years
(median, IQR)
30.3 (29.3) 48.2 (33.3) 0.06
Male (pairs, %) 6 (55%) 10 (71%) 0.93
IVSd, mm
(median, IQR)
15.5 (8.3) 11.5 (10.8) 0.09
LQTS QTc N 25 30
Age, years
(median, IQR)
26.5 (46.8) 32.3 (30.3) 0.13
Male (pairs, %) 13 (52%) 14 (47%) 0.58
QTc, ms
(median, IQR)
464 (49) 462 (76) 0.77
**Significant at the <0.01 level.
As not all data were complete for some pairs, the number of pairs in which we could assess certain traits differs from the number of pairs 
mentioned in table 1.
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; IVSd, diastolic interventricular septum thickness; LQTS, long QT 
syndrome; LVEDD, left ventricular end- diastolic dimension; LVEF, left ventricular ejection fraction; QTc, corrected QT interval.
For QTc values in LQTS, a model describing variation 
with additive genetic effects (AE model) had the best 
fit (p=0.03) with the observed data. In HCM, a model 
describing IVSd variation with shared environmental 
effects (CE model; p=0.02) had the best fit, and the contri-
bution of shared environmental effects on IVSd variation 
was significant (65.6%, 95% CI 20.1% to 83.4%).
dIsCussIon
In this study, we tested our hypothesis that monozygotic 
twins with a mutation that causes either LQTS or a cardi-
omyopathy are more concordant for the main disease 
trait than dizygotic twins or siblings that also carry such a 
mutation. Indeed, we found significantly higher concord-
ance for QTc in monozygotic twins with a long QT causing 
mutation. However, we did not find such high or signif-
icant concordance for the primary cardiomyopathy trait 
of either LVEF or dilatation in DCM, or septal thickening 
in HCM.
In this worldwide collaboration, we collected a higher 
number of twins with a mutation that causes a cardio-
myopathy or channelopathy than to our knowledge 
has been reported previously. We believe that there are 
probably not many more (monozygotic twins) out there 
as this collection is the result of a search in the cohorts 
collected by all major groups active in this field. Although 
this enabled us to study a relatively large number of twins, 
these particular twins are rare and the absolute numbers 
are still low.
Given the sample sizes in this study, varying from 19 
to 55 twin pairs, at a significance level of p value <0.05, 
narrow- sense heritabilities of >0.80, 0.80, 0.60 and 0.55 
could be found with 80% power for LVEF, LVEDD, IVSd 
and QTc, respectively. The power calculations were done 
with functions from Verhulst,22 which use the observed 
twin pair numbers and assume a common variance equal 
or smaller than the observed common variance. This 
suggests the heritability of QTc lengthening in LQTS 
we found is indeed significant. Our findings in LQTS 
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Figure 1 Heritability estimates in percentages using structural equations modelling for primary trait phenotypes in DCM (LVEF 
and LVEDD), HCM (IVSd) and LQTS (QTc). *Significant (within 95% CI). DCM, dilated cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; IVSd, diastolic interventricular septum thickness; LQTS, long QT syndrome; LVEDD, left ventricular end- 
diastolic dimension; LVEF, left ventricular ejection fraction; QTc, corrected QT interval.
Table 3 Heritability estimates as estimated using structural equations modeling (SEM)
Monozygotic 
twin pairs
Control 
pairs SEM (ACE model)
N N h2 (95% CI) C (95% CI)
Best 
model
CE worse
(p value)
AE worse
(p value)
DCM LVEF 8 11 4.9% (0.0% to 84.5%) 66.9% (0.0% to 86.6%) CE – 0.09
LVEDD 7 15 52.8% (0.0% to 91.2%) 24.6% (0.0% to 76.6%) AE 0.23 –
HCM IVSd 11 14 0.0% (0.0% to 43.6%) 65.6% (20.1% to 83.4%)* CE – 0.02*
LQTS QTc 25 30 57.5% (5.5% to 87.5%)* 23.7% (0.0% to 64.9%) AE 0.03* –
*Significant at the p<0.05 level or within the 95% CI.
ACE, additive genetic effects, common and unique environmental effects; AE, additive genetic effects and unique environmental effects; 
CE, common and unique environmental effects; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; IVSd, diastolic 
interventricular septum thickness; LQTS, long QT syndrome; LVEDD, left ventricular end- diastolic dimension; LVEF, left ventricular ejection 
fraction; QTc, corrected QT interval.
confirm findings from other studies on the heritability of 
the QT interval trait.23–30
Our study cannot exclude that there is some heritability 
for structural traits in mutation- induced cardiomyopa-
thies like HCM or DCM, and indeed for LVEDD in DCM 
our results show a trend for considerable heritability. 
However, it does suggest that heritability is less robust in 
these diseases, and that in these diseases a greater influ-
ence of environmental factors on the development of the 
disease trait(s) may be expected. Indeed, for the main 
trait of HCM, thickness of the cardiac septum, we even 
found a statistically significant contribution of environ-
mental effects. The narrow- sense heritability of zero and 
the significant role for the environment on expression 
of septal wall thickness in HCM was unexpected since 
singular reports on monozygotic twins report both discor-
dant14 and concordant twins.15
A downside of the use of data from multiple centres is 
that results may be affected by differing clinical standards 
and interobserver variability. This argument also applies 
to the use of detailed clinical data from clinical publica-
tions on twin pairs with HCM, DCM and LQTS. Because 
ratios within twin pairs have been used for the compar-
ison with other twin pairs, and the two members of each 
pair were observed by the same clinician, we feel that 
interobserver variability does not influence our results. 
Furthermore, the members of each pair were observed 
around the same time, which both minimises intraob-
server variability as well as age- dependent individual 
factors that may influence disease trait development. 
Finally, one may argue that the use of data from clinical 
publications could induce an inclusion bias. However, 
literature describes both concordant and discordant 
phenotypes, suggesting a bias by preferred publication of 
either type was not introduced.
In an effort to increase the number of cases in this 
study, we used dizygotic twin pairs as controls and also 
normal siblings. Both dizygotic twin pairs and normal 
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siblings share 50% of their genome. We did not have 
information on the extent of shared environment for 
the studied cases, and we cannot exclude that this has 
introduced a bias in disease groups where normal siblings 
make up most, or even all of the controls. To minimise 
age- related and sex- related differences, we only selected 
same- sex control pairs and used data from comparable 
time points for all groups.
Many acquired differences can account for the discor-
dant phenotypes we find in monozygotic twin pairs 
that share a disease- causing mutation, including post- 
translational modifications or environmental factors. 
Since we did not find larger differences between older 
twin pairs than younger pairs, it seems that lifetime expo-
sure to environmental factors is not the only explanation 
for this discordance. Early acquired factors may already 
play an important role, as may de novo mutations, copy 
number variations31 and differences in maternally inher-
ited mitochondrial DNA which varies even within an 
individual.32
ConClusIon
We found a significant effect of genetic background on 
the clinical expression of mutations that cause LQTS, but 
did not find such effects for mutations that cause DCM 
and HCM. This suggests that environmental factors may 
be of relatively greater importance to explain differences 
in disease severity in families with a mutation causing 
DCM or HCM. Accordingly, it is anticipated that there 
are more genetic modifiers that underlie incomplete 
penetrance and variable expression of disease genes in 
LQTS, and that studies looking for genetic modifiers in 
heritable heart disease should focus more on disease with 
primary electrical phenotype like LQTS than disease with 
primary structural phenotype like DCM or HCM.
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